nach oben

Erschienen in:

26.04.2023 | Original Article

Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis

verfasst von: An-ju Tan, Dun-chang Mo, Ka Wu, Hong-mei Pan, Dong-mei Wang, Xing-xin Xu, Min-hong Chen, Shu-ying Pan, Rou Li, Wen-jiao lian, Meng-han Wei

Erschienen in: World Journal of Urology | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Few data are available regarding the nephrotoxicity of immune checkpoint inhibitor (ICI) combination therapy in advanced renal cell carcinoma (RCC). This study aimed to investigate the nephrotoxicity of ICI-based combination therapy versus standard of care sunitinib in patients with advanced RCC.

Methods

We searched Embase/PubMed/Cochrane Library for relevant randomized controlled trials (RCTs). Treatment-related nephrotoxicities including increase of creatinine and proteinuria were analyzed by Review Manager 5.4 software.

Results

Seven RCTs involving 5239 patients were included. The analysis showed that ICI combination therapy had similar risks of any grade (RR = 1.03, 95% CI: 0.77–1.37, P = 0.87) and grade 3–5 (RR = 1.48, 95% CI: 0.19–11.66, P = 0.71) increased creatinine compared with sunitinib monotherapy. However, ICI combination therapy was associated with significantly higher risks of any grade (RR = 2.33, 95% CI: 1.54–3.51, P < 0.0001) and grade 3–5 proteinuria (RR = 2.25, 95% CI: 1.21–4.17, P = 0.01).

Conclusions

This meta-analysis suggests that ICI combination therapy shows more nephrotoxicity of proteinuria than sunitinib in advanced RCC, which deserves a high attention in the clinic.

Barata PC, Rini BI (2017) Treatment of renal cell carcinoma: current status and future directions. CA Cancer J Clin 67(6):507–524. https://doi.org/10.3322/caac.21411CrossRefPubMed

Procopio G, Nichetti F, Verzoni E (2020) Pembrolizumab plus axitinib: another step ahead in advanced renal cell carcinoma. Lancet Oncol 21(12):1538–1539. https://doi.org/10.1016/s1470-2045(20)30482-4CrossRefPubMed

Mo DC, Huang JF, Luo PH, Huang SX, Wang HL (2021) Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: a meta-analysis of randomized controlled trials. Clin Immunol 232:108876. https://doi.org/10.1016/j.clim.2021.108876CrossRefPubMed

Rassy E, Flippot R, Albiges L (2020) Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol 12:1758835920907504. https://doi.org/10.1177/1758835920907504CrossRefPubMedPubMedCentral

Zhang ZF, Wang T, Liu LH, Guo HQ (2014) Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS ONE 9(3):e90135. https://doi.org/10.1371/journal.pone.0090135CrossRefPubMedPubMedCentral

Tinawi M, Bastani B (2020) Nephrotoxicity of immune checkpoint inhibitors: acute kidney injury and beyond. Cureus. 12(12):e12204. https://doi.org/10.7759/cureus.12204CrossRefPubMedPubMedCentral

Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O et al (2020) Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol 31(2):435–446. https://doi.org/10.1681/ASN.2019070676CrossRefPubMedPubMedCentral

Chen G, Qin Y, Fan QQ, Zhao B, Mei D, Li XM (2020) Renal adverse effects following the use of different immune checkpoint inhibitor regimens: a real-world pharmacoepidemiology study of post-marketing surveillance data. Cancer Med 9(18):6576–6585. https://doi.org/10.1002/cam4.3198CrossRefPubMedPubMedCentral

Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP et al (2016) Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int 90(3):638–647. https://doi.org/10.1016/j.kint.2016.04.008CrossRefPubMedPubMedCentral

10.

Dolladille C, Akroun J, Morice PM, Dompmartin A, Ezine E et al (2021) Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. Eur Heart J 42(48):4964–4977. https://doi.org/10.1093/eurheartj/ehab618CrossRefPubMed

11.

Jamal S, Hudson M, Fifi-Mah A, Ye C (2020) Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist. J Rheumatol 47(2):166–175. https://doi.org/10.3899/jrheum.190084CrossRefPubMed

12.

Perazella MA, Shirali AC (2018) Nephrotoxicity of cancer immunotherapies: past, present and future. J Am Soc Nephrol 29(8):2039–2052. https://doi.org/10.1681/ASN.2018050488CrossRefPubMedPubMedCentral

13.

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158–168. https://doi.org/10.1056/NEJMra1703481CrossRefPubMed

14.

Qu J, Ding Y, Jiang K, Hao J, Li Y et al (2021) Nephrotoxicity of immune checkpoint inhibitors: a disproportionality analysis from 2013 to 2020. Tohoku J Exp Med 254(4):275–282. https://doi.org/10.1620/tjem.254.275CrossRefPubMed

15.

Rizzo A, Mollica V, Santoni M, Rosellini M, Marchetti A, Massari F (2022) Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials. Future Oncol 18(5):625–634. https://doi.org/10.2217/fon-2021-0888CrossRefPubMed

16.

Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G et al (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45(2):160–169. https://doi.org/10.1159/000455014CrossRefPubMed

17.

Wang DY, Salem J-E, Cohen JV, Chandra S, Menzer C et al (2018) Fatal toxic effects associated with immune checkpoint inhibitors. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2018.3923CrossRefPubMedPubMedCentral

18.

Wu Z, Chen Q, Qu L, Li M, Wang L et al (2022) Adverse events of immune checkpoint inhibitors therapy for urologic cancer patients in clinical trials: a collaborative systematic review and meta-analysis. Eur Urol 81(4):414–425. https://doi.org/10.1016/j.eururo.2022.01.028CrossRefPubMed

19.

Zhou X, Yao Z, Bai H, Duan J, Wang Z et al (2021) Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Lancet Oncol 22(9):1265–1274. https://doi.org/10.1016/s1470-2045(21)00333-8CrossRefPubMed

20.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol 134:178–189. https://doi.org/10.1016/j.jclinepi.2021.03.001CrossRefPubMed

21.

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928. https://doi.org/10.1136/bmj.d5928CrossRefPubMedPubMedCentral

22.

Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31(8):1030–1039. https://doi.org/10.1016/j.annonc.2020.04.010CrossRefPubMed

23.

Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT et al (2021) Nivolumab plus Cabozantinib versus Sunitinib for advanced renal-cell carcinoma. N Engl J Med 384(9):829–841. https://doi.org/10.1056/NEJMoa2026982CrossRefPubMedPubMedCentral

24.

McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI et al (2018) Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med 24(6):749–757. https://doi.org/10.1038/s41591-018-0053-3CrossRefPubMedPubMedCentral

25.

Motzer R, Alekseev B, Rha SY, Porta C, Eto M et al (2021) Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J Med 384(14):1289–1300. https://doi.org/10.1056/NEJMoa2035716CrossRefPubMed

26.

Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF et al (2022) Final Overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus Bevacizumab vs Sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol 8(2):275–280. https://doi.org/10.1001/jamaoncol.2021.5981CrossRefPubMed

27.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ et al (2019) Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20(10):1370–1385. https://doi.org/10.1016/s1470-2045(19)30413-9CrossRefPubMedPubMedCentral

28.

Powles T, Plimack ER, Soulières D, Waddell T, Stus V et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21(12):1563–1573. https://doi.org/10.1016/s1470-2045(20)30436-8CrossRefPubMed

29.

Ning K, Wu Z, Zou X, Liu H, Wu Y, Xiong L, Yu C, Guo S, Han H, Zhou F, Dong P, Zhang Z (2022) Immune checkpoint inhibitors further aggravate proteinuria in patients with metastatic renal cell carcinoma after long-term targeted therapy. Transl Androl Urol 11(3):386–396. https://doi.org/10.21037/tau-21-1015.PMID:35402197;PMCID:PMC898497CrossRefPubMedPubMedCentral

30.

Tomita Y, Uemura H, Fujimoto H, Kanayama HO, Shinohara N et al (2011) Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer 47(17):2592–2602. https://doi.org/10.1016/j.ejca.2011.07.014CrossRefPubMed

31.

Motzer RJ, McDermott DF, Escudier B, Burotto M, Choueiri TK et al (2022) Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer 128(11):2085–2097. https://doi.org/10.1002/cncr.34180CrossRefPubMed

Titel: Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis
verfasst von: An-ju Tan
Dun-chang Mo
Ka Wu
Hong-mei Pan
Dong-mei Wang
Xing-xin Xu
Min-hong Chen
Shu-ying Pan
Rou Li
Wen-jiao lian
Meng-han Wei
Publikationsdatum: 26.04.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2023
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04407-x

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis